<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Normal skeletal development and regulation of bone formation and resorption
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Normal skeletal development and regulation of bone formation and resorption
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Normal skeletal development and regulation of bone formation and resorption
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stavros C Manolagas, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Clifford J Rosen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 29, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The skeleton is a highly dynamic organ that constantly undergoes changes and regeneration. It consists of specialized bone cells, mineralized and unmineralized connective tissue matrix, and spaces that include the bone marrow cavity, vascular canals, canaliculi, and lacunae containing osteocytes. Bone also contains water, which represents at least 25 percent of its wet weight and provides much of its unique strength and resilience.
        </p>
        <p>
         The skeleton has both structural and metabolic functions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Its structural function is critical for locomotion, respiration, and protection of internal organs. The structural connection between the skeleton and the hematopoietic system is particularly intimate; these two systems share both cells and local regulatory factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Its metabolic function is largely as a storehouse for calcium, phosphorus, and carbonate, and it can contribute to buffering changes in hydrogen ion concentration.
        </p>
        <p>
        </p>
        <p>
         This topic will review how the skeleton develops and how the processes of bone formation and resorption are regulated. The pathogenesis of osteoporosis is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2044.html" rel="external">
          "Pathogenesis of osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H593789">
         <span class="h1">
          SKELETAL COMPONENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vertebrate skeleton is subdivided into an axial and an appendicular component. The axial component comprises the skull, spine, sternum, and the ribs. The appendicular component comprises long bones and their appendices. There are two major types of bone in the adult skeleton  (
         <a class="graphic graphic_figure graphicRef58348" href="/z/d/graphic/58348.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cortical bone is dense and compact. It constitutes the outer part of all skeletal structures. The lamellae may be extensive (circumferential) or tightly packed in concentric circles in osteons. Cortical bone comprises 80 percent of the skeletal weight. Its major function is to provide mechanical strength and protection, but it can participate in metabolic responses, particularly when there is severe or prolonged mineral deficit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trabecular (cancellous) bone is found inside the long bones (particularly at the ends), throughout the bodies of the vertebrae, and in the inner portions of the pelvis and other large flat bones. Trabecular bone is an important contributor to mechanical support, particularly in the vertebrae. It is also more metabolically active than cortical bone and provides the initial supplies of mineral in acute deficiency states.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1206084">
         <span class="h1">
          SKELETAL DEVELOPMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Flat bones, including the vault of the skull, most of the upper facial skeleton, parts of the mandible, clavicle, and the pelvis, as well as the collar of long bones, arise from the direct conversion of undifferentiated mesenchymal cells into bone in a process called intramembranous bone formation. The remaining axial and appendicular bone is formed by a multistep process that requires the sequential formation and degradation of cartilaginous structures that serve as a template for the developing bones. Bone formation arising from a cartilaginous template is referred to as endochondral bone formation  (
         <a class="graphic graphic_figure graphicRef68827" href="/z/d/graphic/68827.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         Cartilage is unique among skeletal tissues in its capacity to grow interstitially, ie, by division of chondrocytes. Longitudinal bone growth occurs at the growth plates and involves elongation of the cartilaginous template as a result of the division of chondrocytes as well as increases in their size. The chondrocytes enlarge, form columns, and undergo apoptosis. Then marrow cells enter the space formerly occupied by these cells and the cartilage in between the columns becomes mineralized. Osteoblasts settle on the cartilaginous template and lay down extracellular matrix (osteoid) that calcifies into woven bone. With time, woven bone is resorbed by osteoclasts and replaced with mature trabecular bone made by osteoblasts. This process is responsible for the formation of the spongy, honeycomb-like cancellous bone, and it allows for the formation and expansion of the bone marrow cavity simultaneously with the increase in bone size.
        </p>
        <p>
         Long bones, especially the femur and tibia, are subjected to most of the load during daily activities and they are crucial for skeletal mobility. They grow primarily by elongation of the diaphysis, with an epiphysis at the ends of the growing bone. The ends of epiphyses are covered with a hyaline cartilage ("articular cartilage"). The longitudinal growth of long bones is a result of endochondral ossification at the epiphyseal plate. Bone growth in length is stimulated by the production of a wide variety of hormones including growth hormone (GH) and insulin-like growth factor-1 (IGF-1), sex steroids, thyroxine (T4), and parathyroid hormone (PTH). (See
         <a class="local">
          'Systemic and local regulators of bone cells'
         </a>
         below.)
        </p>
        <p>
         Skeletal development also requires the formation of blood vessels in the bone, and vascular endothelial growth factor (VEGF) signaling is critical for the conversion of avascular cartilage to highly vascular bone [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1206092">
         <span class="h2">
          Cartilage proliferation and differentiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial formation of the skeleton, first as cartilage and then as bone, requires the sequential activity of a large number of genes. Genes of the homeobox family (
         <em>
          Hox, MSX, DLX
         </em>
         ) [
         <a href="#rid3">
          3-6
         </a>
         ] are responsible for the initial differentiation as well as the maintained growth of skeletal tissues. A complex interaction involving parathyroid hormone-related peptide (
         <em>
          PTHRP
         </em>
         ) and the Indian hedgehog (
         <em>
          IHH
         </em>
         ) genes is critical for the development and regulation of the cartilage growth plate [
         <a href="#rid7">
          7,8
         </a>
         ]. Notch signaling is also involved in chondrocyte proliferation and differentiation into bone [
         <a href="#rid9">
          9,10
         </a>
         ]. Bone morphogenetic proteins (BMPs) stimulate bone formation, but orderly growth requires that there also be periods when growth is inhibited or unwanted skeletal tissue is removed.
        </p>
        <p>
         Phosphate has long been known to play an important role in mineralization, but it also can affect cartilage proliferation and differentiation [
         <a href="#rid11">
          11
         </a>
         ]. The most important factor for phosphate regulation is probably fibroblast growth factor 23 (FGF23) that possibly, along with other phosphatonins, plays a role in skeletal development as well as interacting with calcium regulatory hormones in phosphorus homeostasis in bone, kidney, and intestine [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H593737">
         <span class="h2">
          Osteoblasts
         </span>
        </p>
        <p class="headingAnchor" id="H5525058">
         <span class="h3">
          Differentiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteoblasts form the connective tissue matrix, which mineralizes and becomes bone. The precursors of osteoblasts are multipotent mesenchymal stem cells, which also give rise to bone marrow stromal cells, chondrocytes, muscle cells, and adipocytes  (
         <a class="graphic graphic_figure graphicRef79078" href="/z/d/graphic/79078.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid14">
          14-16
         </a>
         ]. Importantly, the osteoblasts responsible for bone formation in different physiologic, pathologic, or pharmacologic conditions are obtained from numerous different sources, including chondrocytes of the growth plate, stromal cells of the bone marrow, quiescent bone lining cells that reside on the bone surface, specialized fibroblasts in sutures and periodontal ligaments, and pericytes adherent to the endothelial layer of vessels [
         <a href="#rid17">
          17,18
         </a>
         ]. Mesenchymal stem cell progenitors of osteoblasts residing on the outer surface of blood vessels are critical for the formation of blood vessels as well [
         <a href="#rid19">
          19-21
         </a>
         ]. The process of differentiation of progenitors to mature osteoblasts (ie, the cells capable of synthesizing the bone matrix) is accomplished by a sequential progression from the least differentiated and most proliferative cell to terminally differentiated cell that can no longer undergo mitosis. At the beginning of the process, mesenchymal stem cells with unlimited self-renewal capacity undergo asymmetric divisions resulting in not only other stem cells, but also daughter cells with limited self-renewal and extensive proliferation capacity. Progressively, the proliferative capacity decreases as differentiation increases.
        </p>
        <p class="headingAnchor" id="H593745">
         <span class="h4">
          Runx2
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Runx2
         </em>
         , a member of the runt homology domain transcription factor family, is critical for the initiation of the osteoblast differentiation process and the commitment of multipotential precursors to osteoprogenitors [
         <a href="#rid22">
          22-24
         </a>
         ].
         <em>
          Runx2
         </em>
         is the earliest differentiation marker of the osteoblast lineage. Together with
         <em>
          Runx3
         </em>
         ,
         <em>
          Runx2
         </em>
         is also required for the maturation of hypertrophic chondrocytes. Deletion of
         <em>
          Runx2
         </em>
         results in the development of a complete cartilaginous skeleton, but no transformation to bone. Hence, the animals die at birth because their soft ribcage cannot support respiration. Heterozygous deletion of one
         <em>
          Runx2
         </em>
         gene results in a human genetic disease called cleidocranial dysplasia [
         <a href="#rid25">
          25,26
         </a>
         ]. Osterix, another transcription factor and a zinc-finger protein, acts downstream of Runx2 and is responsible for the transition of osteoprogenitors to preosteoblasts [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         The nuclear receptor peroxisome proliferator-activated receptor (PPAR)-gamma is a crucial cellular switch in the process of the commitment of the multipotential mesenchymal osteoprogenitors. Activation of PPAR-gamma by its natural ligands (eg, prostaglandin J2 or free fatty acids) or synthetic ligands, like the diabetes drug
         <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">
          rosiglitazone
         </a>
         , suppresses differentiation of the uncommitted progenitors toward the osteoblast lineage while simultaneously promoting differentiation toward the adipocyte lineage [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Cultured preosteoblasts and osteoblasts have a reproducible temporal pattern of collagen and alkaline phosphatase synthesis followed by synthesis of osteocalcin, a protein containing gamma-carboxylated glutamic acid that is produced by cells of osteoblast lineage [
         <a href="#rid29">
          29
         </a>
         ]. In vivo, fully differentiated osteoblasts express the genes for all three of these proteins and for other specialized proteins such as osteopontin and bone sialoprotein.
        </p>
        <p>
         Osteoblasts are functionally and morphologically heterogeneous [
         <a href="#rid30">
          30
         </a>
         ]. During rapid phases of bone formation, they may be columnar in shape, with abundant endoplasmic reticulum, and they synthesize collagen rapidly. When bone formation rates are slower, they are flatter and less metabolically active. Fully differentiated osteoblasts are oriented so that the collagen and noncollagen proteins are laid down on the bone surface in forms suitable for mineralization. Mineralization is delayed for several days, which allows time for collagen cross-linking and the development of large, strong fibers.
        </p>
        <p class="headingAnchor" id="H593753">
         <span class="h4">
          Wnt signaling pathway
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Wnt signaling pathway is another critical regulator of skeletal development and mass, working in part through the stimulation of
         <em>
          Runx2
         </em>
         gene expression [
         <a href="#rid31">
          31
         </a>
         ]. Activation of the canonical Wnt signaling involves the formation of a complex between Wnt proteins, frizzled and low-density lipoprotein receptor-related protein 5 (LRP5) or LRP6 receptors [
         <a href="#rid32">
          32,33
         </a>
         ]. This complex in turn leads to phosphorylation and inactivation of glycogen synthase kinase (GSK)-3beta, inhibition of beta-catenin degradation, and subsequent accumulation of beta-catenin in the nucleus [
         <a href="#rid34">
          34
         </a>
         ]. Nuclear beta-catenin binds the Tcf/Lef family of transcription factors and induces target gene expression [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Genetic studies in mice in which the activity of beta-catenin was manipulated have established that beta-catenin is indeed essential for the specification of osteoblasts from mesenchymal precursor cells through effects on both the proliferation and maturation of the precursor pool [
         <a href="#rid36">
          36-38
         </a>
         ]. Moreover, it is now clear that beta-catenin suppresses the alternative chondrocyte fate of the precursor cells [
         <a href="#rid39">
          39
         </a>
         ]. Besides its role in promoting osteoblastogenesis, deletion or activation of beta-catenin at a later stage of osteoblast differentiation leads to an increase or suppression of osteoclastogenesis, respectively, through regulation of osteoprotegerin (OPG) [
         <a href="#rid40">
          40,41
         </a>
         ]. Modulation of beta-catenin levels at this later stage of osteoblast differentiation had no apparent effect on osteoblast function.
        </p>
        <p>
         Osteocytes are the predominant cellular source of the Wnt antagonist sclerostin, a limiting factor for osteoblast generation and bone mass accrual that mediates the homeostatic adaptation of bone to mechanical loading [
         <a href="#rid42">
          42
         </a>
         ]. Sclerostin is the product of the
         <em>
          SOST
         </em>
         gene and a negative regulator of Wnt signaling [
         <a href="#rid43">
          43
         </a>
         ]. It binds to both LRP5 and LRP6 and prevents activation of the Wnt receptor complex [
         <a href="#rid44">
          44,45
         </a>
         ]. This results in inhibition of bone formation [
         <a href="#rid46">
          46
         </a>
         ]. In addition to sclerostin, the DKK family members, particularly DKK-1 (Dickkopf-1), inhibit the Wnt pathway by binding to the LPR5/6 receptor [
         <a href="#rid47">
          47
         </a>
         ]. Wnt signaling can also be blocked by other proteins, such as soluble frizzled-related protein, that bind to Wnt ligands [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         Disruption in the Wnt signaling pathway results in profound changes in skeletal homeostasis [
         <a href="#rid49">
          49
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mutations in
         <em>
          WNT1
         </em>
         impair bone formation [
         <a href="#rid50">
          50
         </a>
         ]. A heterozygous missense mutation in
         <em>
          WNT1
         </em>
         (c. 652T to G) causes severe, early-onset, dominantly inherited osteoporosis, and a homozygous nonsense mutation (c. 884C to A) causes a severe form of osteogenesis imperfecta.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss- or gain-of-function mutations in
         <em>
          LRP5
         </em>
         causes osteoporosis-pseudoglioma syndrome [
         <a href="#rid51">
          51
         </a>
         ] or the hereditary high-bone-mass trait, respectively [
         <a href="#rid52">
          52-54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic disorders in which sclerostin production is decreased are associated with increased bone mass [
         <a href="#rid55">
          55
         </a>
         ], and antibodies to sclerostin can increase bone formation [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The anabolic effects of PTH and mechanical loading may involve enhanced Wnt signaling via downregulation of sclerostin activation of LRP5 [
         <a href="#rid57">
          57-60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inactivation of DKK family members can increase bone mass [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Wnt pathway is also a major regulator of joint remodeling and tumor necrosis factor (TNF)-alpha induction of DKK-1 results in the joint erosion characteristically seen in rheumatoid arthritis [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H594350">
         <span class="h3">
          Apoptosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sixty to 80 percent of osteoblasts die by apoptosis. The remaining become either lining cells that spread out and cover quiescent bone surfaces or are entombed individually in lacunae of the mineralized matrix as osteocytes. The lining cells remain connected to the osteocytes, which may be necessary for transmitting the activation signal during remodeling.
        </p>
        <p>
         An increase in reactive oxygen species (ROS) has been implicated in the decreased bone formation associated with advancing age [
         <a href="#rid62">
          62
         </a>
         ]. In line with this evidence, oxidative stress caused by increased ROS production in osteoblasts stimulates apoptosis and decreases bone formation [
         <a href="#rid63">
          63-65
         </a>
         ]. To protect against oxidative stress, organisms ranging from prokaryotes to mammals scavenge ROS by a network of overlapping mechanisms including various forms of superoxide dismutases (SODs) and catalase as well as thiol-containing oligopeptides with redox-active sulfhydryl moieties, the most abundant of which are glutathione and thioredoxin [
         <a href="#rid66">
          66
         </a>
         ]. Reduction of these scavenging mechanisms, along with increased mitochondrial respiratory chain leakage and increased activity of membrane oxidases, are the three main mechanisms for oxidative stress.
        </p>
        <p>
         FoxO transcription factors are another important defense mechanism against oxidative stress, serving primarily to maintain the integrity of long-lived cells including tissue stem cells. Consistent with this, global deletion of FoxOs recapitulates the effects of old age on the murine skeleton in young mice within five weeks, suggesting that FoxO-dependent oxidative defense provides a mechanism to handle the oxygen free radicals constantly generated by the aerobic metabolism of osteoblasts and is thereby indispensable for bone mass homeostasis throughout life. While defending against oxidative stress, FoxOs attenuate Wnt signaling and its potent influence on bone mass [
         <a href="#rid67">
          67,68
         </a>
         ]. Indeed, in the setting of oxidative stress, the limited pool of beta-catenin in osteoblast progenitors is diverted from Wnt/Tcf- to FoxO-mediated transcription [
         <a href="#rid67">
          67
         </a>
         ]. This diversion leads to suppressed osteoblastogenesis and is associated with the old age-dependent decrease in osteoblast number and bone formation in the murine skeleton [
         <a href="#rid67">
          67,68
         </a>
         ], and it may contribute to several other age-related pathologies [
         <a href="#rid69">
          69-73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H594407">
         <span class="h2">
          Osteocytes
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the process of their entombment within the mineralized matrix, osteocytes undergo a dramatic morphologic transformation that includes the development of an average of 50 slender cytoplasmic processes that radiate from the cell body and give osteocytes the resemblance of neuronal cells [
         <a href="#rid74">
          74
         </a>
         ]. The processes run like buried cable along narrow canaliculi and are linked by gap junctions with the processes of neighboring osteocytes, as well as cells present on the bone surface, including the lining cells and cellular elements of the bone marrow and the endothelial cell of the bone marrow vasculature  (
         <a class="graphic graphic_figure graphicRef73524" href="/z/d/graphic/73524.html" rel="external">
          figure 4
         </a>
         ). Unlike osteoclasts and osteoblasts, which are relatively short lived and transiently present only on a small fraction of the bone surface, osteocytes are deployed throughout the skeleton, are long lived, and are far more abundant than either osteoclasts (1000 times) or osteoblasts (10 times) [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         Osteocytes and their dendritic processes are surrounded by a gel-like matrix that is in continuity with the peripheral circulation [
         <a href="#rid76">
          76,77
         </a>
         ]. Transport of solutes through the lacunar-canalicular system is accommodated in part by hydraulic vascular pressure and in part by diffusion and convection induced by mechanical forces. Transmission of fluid shear stresses to the cytoskeleton by the matrix is essential for the ability of osteocytes to sense mechanical loading and choreograph the adaptation of bone to the prevailing mechanical forces. Cilia tether the osteocytes to the collagen, allowing them to sense fluid shifts. Osteocytes secrete growth factors that regulate bone formation. Mature osteocytes tonically secrete sclerostin to maintain an inhibition of bone formation, but when mechanical forces are applied to the bone, the osteocytes stop secreting sclerostin and bone formation is initiated on the bone surface.
        </p>
        <p class="headingAnchor" id="H593827">
         <span class="h2">
          Osteoclasts
         </span>
        </p>
        <p class="headingAnchor" id="H3804263">
         <span class="h3">
          Development
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteoclasts are terminally differentiated, multinucleated cells that are uniquely capable of digesting calcified bone matrix. They are formed by fusion of mononuclear precursors of the monocyte/macrophage lineage  (
         <a class="graphic graphic_figure graphicRef79078" href="/z/d/graphic/79078.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid78">
          78,79
         </a>
         ]. The receptor activator of nuclear factor kappa-B ligand (RANKL) and the macrophage colony-stimulating factor (M-CSF) are two cytokines that are essential for the development, function, and survival of osteoclasts [
         <a href="#rid80">
          80,81
         </a>
         ], and nuclear factor of activated T cells 1 (NFATc1) is the master transcription factor responsible for osteoclast differentiation and function [
         <a href="#rid81">
          81,82
         </a>
         ]. Osteocytes are the main cellular source of the RANKL that is required for osteoclast generation during bone remodeling [
         <a href="#rid83">
          83
         </a>
         ]. However, it is currently unclear whether during remodeling RANKL is produced by apoptotic osteocytes or live osteocytes responding to the death of their neighbors [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         RANKL interacts with a receptor on osteoclast precursors that is identical to the receptor involved in interaction of T-cells and dendritic cells called RANK  (
         <a class="graphic graphic_figure graphicRef61626" href="/z/d/graphic/61626.html" rel="external">
          figure 5
         </a>
         ). NFATc1 is induced by RANKL and coactivated by immunoglobulin-like receptors and their associated adapter proteins. RANKL can also bind to a protein called OPG or osteoclastogenesis inhibitory factor [
         <a href="#rid85">
          85-89
         </a>
         ]. Administration of a single dose of osteoprotegerin or an antibody to RANKL to postmenopausal women results in rapid reduction of biochemical markers of bone turnover and increase in BMD [
         <a href="#rid90">
          90,91
         </a>
         ].
        </p>
        <p>
         ROS,
         <strong>
         </strong>
         in contrast to their negative effects on osteoblasts, are a critical requirement for RANKL-induced osteoclast generation, activation, and survival [
         <a href="#rid92">
          92-94
         </a>
         ]. RANKL increases ROS through a cascade involving TRAF6, Rac1, and NADPH oxidase  (
         <a class="graphic graphic_figure graphicRef61626" href="/z/d/graphic/61626.html" rel="external">
          figure 5
         </a>
         ) [
         <a href="#rid92">
          92,95-99
         </a>
         ]. ROS also play an important role in M-CSF-induced monocyte survival [
         <a href="#rid100">
          100
         </a>
         ]. Conversely, decreased ROS levels caused by the administration of the antioxidant N-acetyl cysteine (NAC), inhibition of NADPH oxidase (Nox1), a dominant negative rac1, or overexpression of glutathione peroxidase (Gpx) prevents RANKL-induced JNK, p38, and ERKs activation and osteoclastogenesis [
         <a href="#rid92">
          92,99
         </a>
         ]. Several different antioxidants prevent the increased bone resorption that follows loss of sex steroids [
         <a href="#rid65">
          65,101
         </a>
         ]. Moreover, mitochondrial biogenesis and ROS production coupled with iron uptake through transferrin receptor 1 (TfR1) and iron supply to mitochondrial respiratory proteins are essential for the bone-resorbing function of osteoclasts and the bone loss caused by estrogen deficiency [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3804381">
         <span class="h3">
          Function
         </span>
         <span class="headingEndMark">
          —
         </span>
         As they mature, osteoclasts undergo dramatic reorganization of their cytoskeleton. Filamentous actin (F-actin) is first organized into podosomes, highly dynamic structures that mediate cell adhesion and migration of osteoclasts. When osteoclasts adhere on bone, F-actin forms a ring-like structure (actin-ring) at the sealing zone, a tight adhesion structure where the osteoclast plasma membrane is juxtaposed to bone [
         <a href="#rid20">
          20
         </a>
         ]. The sealing zone surrounds a specialized plasma membrane domain, the ruffled border, thus forming an isolated resorptive microenvironment between the osteoclast and the underlying bone matrix. The ruffled border is generated by the fusion of secretory vesicles with the bone apposing plasma membrane. During this process, protons and lysosomal enzymes (predominantly cathepsin K) are vectorially secreted into the resorption lacuna to dissolve bone mineral and digest organic matrix, respectively [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
         The functional differentiation of osteoclasts involves the expression of several genes. Deletion of the c-src, c-fos, and PU-1 genes results in an osteopetrotic phenotype associated with inadequate formation or activity of osteoclasts [
         <a href="#rid104">
          104
         </a>
         ]. Critical functional proteins include: integrin receptors for sealing zone attachment, a hydrogen-potassium ATPase for hydrogen ion secretion, chloride channels, and cathepsin K. Mononuclear osteoclast precursors express the genes for these proteins and for calcitonin receptors during differentiation.
        </p>
        <p>
         The final activation step probably involves binding of integrins to proteins on the mineralized bone surface that are either already present or are secreted by the osteoclasts [
         <a href="#rid105">
          105
         </a>
         ]. The life span of osteoclasts is probably limited because of programmed death of the nuclei (apoptosis). Estrogen and transforming growth factor (TGF)-beta may decrease bone resorption by stimulating apoptosis [
         <a href="#rid106">
          106-108
         </a>
         ].
        </p>
        <p>
         Osteoclasts remove mineral and matrix to a limited depth on the trabecular surface or within cortical bone. It is unclear what stops this process, but high local concentrations of calcium or substances released from the matrix may be involved [
         <a href="#rid109">
          109,110
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among the stimulators of osteoclast generation (some of which act indirectly) are calcitriol, PTH, TNF-alpha, prostaglandin E2, interleukin (IL)-1, IL-6, IL-11, and IL-17.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among the inhibitors of osteoclast generation are several interleukins (IL-4,-12,-13,-18). Interferon-gamma (IFNg) appears to have a direct inhibitory effect and an indirect stimulatory effect [
         <a href="#rid111">
          111,112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1206099">
         <span class="h1">
          BIOCHEMISTRY OF BONE MINERAL MATRIX
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bone is composed of an orderly collagen matrix on which calcium and phosphate are deposited in the form of hydroxyapatite. Collagen is deposited in a lamellar fashion and strengthened by multiple crosslinks, both within and between the triple-helical collagen molecules. These crosslinks are pyridinolines that are resistant to degradation and are released during bone resorption, either as free or peptide forms that can be measured in serum and urine. (See
         <a class="medical medical_review" href="/z/d/html/2047.html" rel="external">
          "Bone physiology and biochemical markers of bone turnover"
         </a>
         .)
        </p>
        <p>
         The matrix also contains noncollagen proteins that are critical for regulating mineralization and strengthening the collagen backbone [
         <a href="#rid113">
          113
         </a>
         ]. The calcium-binding proteins include osteocalcin (bone Gla protein) and matrix Gla protein, which contain gamma carboxyglutamic acid and are vitamin K-dependent, similar to many clotting factors (see
         <a class="medical medical_review" href="/z/d/html/1318.html" rel="external">
          "Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"
         </a>
         ). Osteocalcin increases bone quality and strength by adjusting the alignment of biological apatite crystallites parallel to collagen fibrils; however, it plays no role in bone formation, resorption, or bone mass acquisition [
         <a href="#rid114">
          114
         </a>
         ]. Earlier suggestions that osteocalcin may be a hormone have been contested by preclinical animal studies as well as clinical evidence in humans [
         <a href="#rid115">
          115
         </a>
         ]. Bone sialoprotein and osteopontin bind both calcium and collagen and may play a role in the adherence of osteoclasts to the bone surface.
        </p>
        <p>
         The bone mineral is composed of complex, often incomplete, crystals of hydroxyapatite. The crystals may contain carbonate, fluoride, and a variety of trace minerals, depending on the environment in which the skeleton grows. They are relatively small, which is appropriate for a structure that can undergo strain with minimal microdamage. Mineralization is probably limited not only by the packing of the collagen fibers, but also by substances present on the bone crystal surface such as pyrophosphate.
        </p>
        <p class="headingAnchor" id="H1207796">
         <span class="h1">
          BONE MODELING AND REMODELING
         </span>
         <span class="headingEndMark">
          —
         </span>
         During development and growth, the skeleton is sculpted to achieve its shape and size by the removal of bone from one site and deposition at a different one; this process is called modeling. After the skeleton has reached maturity, regeneration continues in the form of a periodic replacement of old bone with new at the same location [
         <a href="#rid116">
          116
         </a>
         ]. This process is called remodeling
         <strong>
         </strong>
         and is responsible for the complete regeneration of the adult skeleton every 10 years.
        </p>
        <p>
         Bone remodeling begins early in skeletal development. Endochondral remodeling in the primary spongiosa converts the relatively weak spicules of calcified cartilage into strong trabecular bone. Haversian remodeling in the cortex occurs in larger bones and is probably necessary to maintain the viability of cells far from the bone surface. Haversian remodeling is probably also important in repairing fatigue damage to the skeleton.
        </p>
        <p>
         Removal of bone (resorption) is the task of osteoclasts. Formation of new bone is the task of osteoblasts. Both of these processes are controlled by the osteocytes [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1206106">
         <span class="h2">
          Modeling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Growth of the skeleton and changes in bone shape are produced by modeling. Linear growth during childhood and adolescence occurs by growth of cartilage at the end plates, followed by endochondral bone formation  (
         <a class="graphic graphic_figure graphicRef68827" href="/z/d/graphic/68827.html" rel="external">
          figure 2
         </a>
         ). The width of the bones increases by periosteal apposition. During childhood, this is accompanied by endosteal resorption. The endosteal (or inner) surface is in contact with the marrow; thus, endosteal resorption results in a concomitant enlargement of the marrow cavity.
        </p>
        <p>
         During puberty and early adult life, endosteal apposition and trabecular thickening provide maximum skeletal mass and strength (peak bone mass) [
         <a href="#rid117">
          117
         </a>
         ]. These processes are influenced by locally and systemically produced factors and mechanical forces.
        </p>
        <p class="headingAnchor" id="H1206113">
         <span class="h2">
          Remodeling
         </span>
         <span class="headingEndMark">
          —
         </span>
         The purpose of remodeling in the adult skeleton is unclear but most likely it serves to remove dead osteocytes, maintain oxygen and nutrient supply and the appropriate level of matrix hydration, and repair fatigue damage, thus preventing excessive aging and its consequences. Remodeling, with positive balance, does occur in the growing skeleton as well. Its purpose, quite different from that proposed for the adult skeleton, is to expand the marrow cavity while increasing trabecular thickness [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
         The stages of the remodeling cycle (resorption, reversal, formation) have different lengths. Resorption probably continues for approximately two weeks. The reversal phase may last up to four or five weeks, while formation can continue for four months until the new bone structural unit is fully formed. Because bone resorption precedes and is faster than bone formation, when there is a sudden increase in the remodeling rate, there is always a temporary imbalance, termed the remodeling space.
        </p>
        <p class="headingAnchor" id="H3804279">
         <span class="h3">
          Bone multicellular unit
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most of the adult skeleton consists of bone that is remodeled periodically by temporal anatomic units comprising osteoclasts and osteoblasts, termed bone multicellular units (BMU)  (
         <a class="graphic graphic_picture graphicRef75617" href="/z/d/graphic/75617.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid118">
          118
         </a>
         ]. All osteoclasts and osteoblasts belong to a BMU [
         <a href="#rid118">
          118
         </a>
         ]. Although during modeling, one cannot distinguish anatomical units analogous to BMU per se, sculpting of the growing skeleton requires spatial and temporal orchestration of the destination of osteoblasts and osteoclasts, albeit with different rules and coordinates to those operating in the BMU of the remodeling skeleton.
        </p>
        <p>
         The BMU, approximately 1 to 2 mm long and 0.2 to 0.4 mm wide, comprises a team of osteoclasts in the front, a team of osteoblasts in the rear, a central vascular capillary, a nerve supply, and associated connective tissue. In healthy human adults, three to four million BMUs are initiated per year and approximately one million are operating at any moment. Each BMU begins at a particular place and time (origination) and advances toward a target, which is a region of bone in need of replacement, and for a variable distance beyond its target (progression) and eventually comes to rest (termination) [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
         In cortical bone, the BMU (also termed osteon) travels through the bone, excavating and replacing a tunnel (Haversian canal). In cancellous bone, the BMU moves across the trabecular surface, excavating and replacing a trench (Howship's lacunae). In both situations, the cellular components of the BMUs maintain a well-orchestrated spatial and temporal relationship with each other. Osteoclasts adhere to bone and subsequently remove it by acidification and proteolytic digestion. As the BMU advances, osteoclasts leave the resorption site and osteoblasts move in to cover the excavated area and begin the process of new bone formation by secreting osteoid, which is eventually mineralized into new bone. In normal adults, bone resorption and bone formation are tightly balanced so that the amount of bone formed in new BMUs equals the amount of bone resorbed.
        </p>
        <p>
         One or more capillaries are always in close proximity to the teams of the osteoclasts and osteoblasts that remodel bone and are most likely the conduits by which osteoclast precursors reach the site that is targeted for remodeling [
         <a href="#rid20">
          20,120
         </a>
         ]. In cancellous bone, blood vessels are juxtaposed to a canopy of flat cells that separates the BMU from the bone marrow [
         <a href="#rid121">
          121
         </a>
         ]. Low oxygen tension, developed as the bone matrix expands, stimulates the expression of endothelial growth factors by osteoblasts and initiates a neovasculogenic program [
         <a href="#rid1">
          1,122,123
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3804366">
         <span class="h3">
          Signaling pathways
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertrophic chondrocytes and osteocytes are essential sources of the receptor activator of nuclear factor kappa B ligand (RANKL) that controls mineralized cartilage resorption and bone remodeling, respectively [
         <a href="#rid83">
          83,124
         </a>
         ]. Newer studies of cultured cells show that osteocytes express a much higher amount of RANKL and have a greater capacity to support osteoclastogenesis in vitro than osteoblasts, and mice with deletion of the RANKL gene in osteocytes have increased bone mass. Contrary to the older paradigm, RANKL produced by mature osteoblasts or their progenitors does not seem to contribute to adult bone remodeling. The rate-limiting step of matrix resorption is controlled by cells embedded within the matrix itself. This evidence provides a mechanistic explanation for the view that at least some remodeling is a targeted (as opposed to stochastic) process in which cells that can sense mechanical strains [
         <a href="#rid125">
          125
         </a>
         ] or matrix damage [
         <a href="#rid126">
          126
         </a>
         ] act as beacons for excavation and repair of a specific region of bone. Similarly, hypertrophic chondrocytes may sense signals that initiate transformation of the cartilage scaffold into bony trabeculae. In both cases, the cells that can best detect the need for matrix removal directly control the process.
        </p>
        <p>
         During the last few years, it has become evident that osteocytes are the choreographers of the remodeling process on the bone surface by virtue of their ability to: sense worn-out bone, direct the homing of osteoclasts (and perhaps osteoblasts) to the site that is in need of remodeling, produce the RANKL and sclerostin that regulate osteoclast and osteoblast generation, respectively  (
         <a class="graphic graphic_figure graphicRef50298" href="/z/d/graphic/50298.html" rel="external">
          figure 6
         </a>
         ), and control and modify the mineralization of the matrix produced by osteoblasts [
         <a href="#rid127">
          127
         </a>
         ]. Mechanical forces sustain osteocyte survival. Conversely, diminished mechanical forces eliminate the necessary signals that sustain osteocyte survival, thereby leading to their apoptosis. Moreover, osteocytes are critical mediators of the homeostatic adaptation of bone to mechanical forces. On the other hand, disruption of the integrity of the osteocyte network leads to inappropriate remodeling and in and of itself compromises bone strength independently of changes in bone mass [
         <a href="#rid128">
          128
         </a>
         ]. Furthermore, osteocytes control and modify the mineralization of the matrix produced by osteoblasts by secreting factors such as matrix extracellular phosphoglycoprotein (MEPE) and the phosphaturic hormone fibroblast growth factor 23 (FGF23) [
         <a href="#rid127">
          127,129
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1207804">
         <span class="h3">
          Resorption
         </span>
         <span class="headingEndMark">
          —
         </span>
         The bone remodeling cycle begins with osteoclast generation and recruitment to a particular site. Under physiologic conditions, such site may be in need for repair, while under pathologic conditions, it may be randomly and inappropriately targeted.
        </p>
        <p class="headingAnchor" id="H1206120">
         <span class="h3">
          Reversal
         </span>
         <span class="headingEndMark">
          —
         </span>
         After osteoclastic resorption is completed, there is a reversal phase in which mononuclear cells, possibly of monocyte/macrophage lineage, appear on the bone surface. These cells could prepare the surface for new osteoblasts to begin bone formation. A layer of glycoprotein-rich material is laid down on the resorbed surface, the so-called "cement line," to which the new osteoblasts can adhere. Osteopontin may be a key protein in this process [
         <a href="#rid130">
          130
         </a>
         ]. The cells at the reversal site may also provide signals for osteoblast differentiation and migration.
        </p>
        <p class="headingAnchor" id="H1206127">
         <span class="h3">
          Formation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The formation phase follows, with successive waves of osteoblasts laying down bone until the resorbed bone is completely replaced and a new bone structural unit is fully formed. When this phase is complete, the surface is covered with flattened lining cells, and there is a prolonged resting period with little cellular activity on the bone surface until a new remodeling cycle begins.
        </p>
        <p class="headingAnchor" id="H244951">
         <span class="h3">
          Mineralization
         </span>
         <span class="headingEndMark">
          —
         </span>
         The newly formed osteoid begins to mineralize after approximately two weeks. This process involves accumulation of matrix molecules. Mineralization occurs rapidly at first, then more slowly. It takes several years for a bone structural unit to become fully mineralized.
        </p>
        <p class="headingAnchor" id="H1206134">
         <span class="h1">
          ABNORMAL BONE REMODELING
         </span>
         <span class="headingEndMark">
          —
         </span>
         In normal adults, bone resorption and bone formation are tightly balanced so that the amount of bone formed in new bone multicellular units (BMUs) equals the amount of bone resorbed. The mechanism(s) of normal balancing is unknown but probably involves several factors released from the bone matrix during osteoclastic bone resorption, such as transforming growth factor (TGF)-beta [
         <a href="#rid131">
          131-133
         </a>
         ], factors produced by osteocytes, such as sclerostin, as well as mechanical needs or hormonal changes. High or low rates of remodeling with an imbalance between resorption and formation can be associated with decreased or increased bone mass.
        </p>
        <p>
         The rate of bone remodeling is very high during bone growth with total body bone formation exceeding resorption, but slows considerably thereafter and the volume of bone formed by each BMU declines with advancing age [
         <a href="#rid62">
          62
         </a>
         ]. Normal parathyroid hormone (PTH) production is an important determinant of the basal rate of remodeling, and patients with congenital, autoimmune, or surgical hypoparathyroidism have low remodeling rates [
         <a href="#rid134">
          134
         </a>
         ]. Other hormonal changes such as menopause or loss of androgens in castrated males, hyperthyroidism, or primary hyperparathyroidism accelerate the rate of remodeling. In the case of the loss of sex steroid, the increased rate of remodeling is transient and returns to baseline within 5 to 10 years (unless there is vitamin D deficiency and secondary hyperparathyroidism), perhaps because of compensatory mechanisms. An oversupply of osteoclasts relative to the need for remodeling or an undersupply of osteoblasts relative to the need for cavity repair are the seminal pathophysiological cellular changes in the most common bone diseases, including osteoporosis [
         <a href="#rid135">
          135,136
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3804447">
         <span class="h2">
          Low bone mass
         </span>
         <span class="headingEndMark">
          —
         </span>
         An oversupply of osteoclasts can result in excessive resorption depth, which can lead to complete loss of trabecular structures. The resulting perforations and discontinuities convert the normal plate-like trabecular architecture to a much weaker system of rods, some of which have free, disconnected ends  (
         <a class="graphic graphic_diagnosticimage graphicRef72620" href="/z/d/graphic/72620.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef51633" href="/z/d/graphic/51633.html" rel="external">
          figure 7
         </a>
         ). There is no template for bone formation at the perforations, and no formation occurs at the free ends of the trabeculae, perhaps because they are not subject to mechanical stress. Complete removal of template also occurs physiologically. As long bones grow, the metaphyseal trabecular bone area decreases as the secondary spongiosa is completely resorbed and the marrow space expands.
        </p>
        <p>
         Bone thinning can also occur without perforation when the extent of resorption or the number of resorbing sites is increased. Osteoblasts normally completely fill the resorption cavity [
         <a href="#rid137">
          137
         </a>
         ]; if this does not occur, the BMU is incomplete, which results in decreased "wall thickness" in trabecular bone. This is the histologic hallmark of osteoporosis in older patients or patients treated with glucocorticoids [
         <a href="#rid138">
          138
         </a>
         ], and it is the result of a decrease in the amount of bone formed by the team of osteoblasts within each BMU.
        </p>
        <p class="headingAnchor" id="H3804440">
         <span class="h2">
          High bone mass
         </span>
         <span class="headingEndMark">
          —
         </span>
         Remodeling imbalance can also occur because of failure of the resorptive process. This can result in dense bones (osteopetrosis or osteosclerosis) and impaired hematopoiesis. As described above, macrophage colony-stimulating factor (M-CSF, CSF-1) is required to initiate osteoclast differentiation. There are osteopetrotic mice that do not make M-CSF, and the osteopetrotic gene locus maps to the same region of chromosome 3 as the M-CSF gene [
         <a href="#rid139">
          139
         </a>
         ]. The applicability of this mechanism to osteopetrosis in humans is unknown. However, other genetic abnormalities have been identified that lead to osteosclerosis, including defects in the genes for ion transport in osteoclasts [
         <a href="#rid140">
          140-143
         </a>
         ].
        </p>
        <p>
         In humans, the most common mutation linked to osteopetrosis is a defect in the osteoclast-specific proton-pump subunit (
         <em>
          TCIRG1
         </em>
         ); 60 percent of patients with severe autosomal recessive osteopetrosis have this mutation [
         <a href="#rid144">
          144
         </a>
         ]. Other clinically significant mutations have been identified in
         <em>
          CLCN7
         </em>
         , a gene that encodes an osteoclast-specific chloride channel;
         <em>
          OSTM1
         </em>
         , a gene that may be involved in Wnt signaling; and in
         <em>
          CAII
         </em>
         , the carbonic anhydrase II gene. These mutations are associated with normal or elevated numbers of abnormally functioning osteoclasts [
         <a href="#rid144">
          144-146
         </a>
         ]. In contrast, mutations in receptor activator of nuclear factor kappa-B ligand (RANKL) result in an osteoclast poor form of osteopetrosis [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p>
         In addition to increases in bone density due to impaired resorption, bone density can be increased by greater stimulation of bone formation or by a combination of the two. This probably is the mechanism for increased bone mass in so-called autosomal dominant type I osteopetrosis in which an activating mutation in the low-density lipoprotein receptor-related protein 5 (
         <em>
          LRP5
         </em>
         ) gene leads to activation of the Wnt signaling pathway and promotion of osteoblastogenesis [
         <a href="#rid53">
          53,148
         </a>
         ]. Sclerostin is a major antagonist of the Wnt signaling pathway (see
         <a class="local">
          'Wnt signaling pathway'
         </a>
         above). Loss-of-function mutations in the gene for sclerostin (
         <em>
          SOST
         </em>
         ) have been described and are also associated with high bone mass [
         <a href="#rid149">
          149,150
         </a>
         ]. The anabolic effect of intermittent PTH administration may also be due in part to suppression of sclerostin, decreased osteoblast and osteocyte apoptosis, and decreased oxidative stress [
         <a href="#rid151">
          151
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1207811">
         <span class="h1">
          SYSTEMIC AND LOCAL REGULATORS OF BONE CELLS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many systemic hormones, cytokines, growth factors, and local signals influence the birth, death, and function of bone cells. The major systemic regulators are the calcium-regulating hormones, parathyroid hormone (PTH), calcitriol, growth hormone (GH)/insulin-like growth factor-1 (IGF-1), glucocorticoids, thyroid hormones, and sex hormones. Other factors, such as IGFs, have both systemic and local effects, and some have mainly or solely local effects, particularly prostaglandins, transforming growth factor (TGF)-beta, bone morphogenetic proteins (BMPs), and cytokines.
        </p>
        <p class="headingAnchor" id="H1206142">
         <span class="h2">
          Parathyroid hormone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parathyroid hormone (PTH) is the most important regulator of calcium homeostasis. It maintains serum calcium concentrations by stimulating bone resorption, increasing renal tubular calcium reabsorption, and increasing renal calcitriol production. PTH stimulates bone formation when given intermittently, but inhibits collagen synthesis at high concentrations [
         <a href="#rid152">
          152,153
         </a>
         ]. It stimulates bone resorption when given (or secreted) continuously, a process mediated by osteoclasts. It also stimulates gene expression in these cells and increases the production of several local factors, including interleukin (IL)-6, IGF-1, an IGF-binding protein (IGF-BP-5), and prostaglandins. The effects of PTH on bone development and remodeling, as well as renal vitamin D activation and organismal calcium homeostasis, result from PTH receptor 1 signaling and inhibition of salt-inducible kinases
         <em>
          Sik2
         </em>
         and
         <em>
          Sik3
         </em>
         via cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) phosphorylation [
         <a href="#rid154">
          154,155
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2050.html" rel="external">
          "Parathyroid hormone secretion and action"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1206149">
         <span class="h2">
          Calcitriol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Calcitriol increases intestinal calcium and phosphorus absorption, thereby promoting bone mineralization. At high concentrations, under conditions of calcium and phosphate deficiency, it also stimulates bone resorption, thereby helping to maintain the supply of these ions to other tissues. Calcitriol stimulates osteoclastogenesis in cell cultures, but animals lacking vitamin D have relatively normal bone growth and remodeling during development, as long as calcium and phosphate are maintained [
         <a href="#rid156">
          156
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1206156">
         <span class="h2">
          Sex steroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both estrogens and androgens have profound effects on bone homeostasis. Estrogen acts directly on cells of both the osteoblastic and osteoclastic lineage [
         <a href="#rid107">
          107,108,157
         </a>
         ] and influences skeletal development in all individuals. In late puberty, estrogens decrease bone turnover by inhibiting bone resorption and they are necessary for epiphyseal closure in both females and males. Thus, males with genetic loss of estrogen receptors or of the aromatase enzyme that converts androgen to estrogen have delayed bone age and decreased bone accrual and delayed epiphyseal closure [
         <a href="#rid158">
          158
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2044.html" rel="external">
          "Pathogenesis of osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1206163">
         <span class="h2">
          Calcitonin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Calcitonin inhibits osteoclasts and therefore bone resorption in pharmacologic doses. However, its physiologic role is minimal in the adult human skeleton. Its pharmacologic effects are transient, probably because of receptor downregulation. As a result, it is only transiently effective in treating hypercalcemia due to excessive bone resorption. (See
         <a class="medical medical_review" href="/z/d/html/850.html" rel="external">
          "Treatment of hypercalcemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1206170">
         <span class="h2">
          Growth hormone and IGFs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The growth hormone (GH)/insulin-like growth factor-1 (IGF-1) system and IGF-2 are important for skeletal growth, especially growth at the cartilaginous end plates and endochondral bone formation. The actions of the IGFs are in part determined by the availability of the various IGF-BPs; IGF-BP-3 is the major determinant of serum IGF concentrations, while IGF-BP-5 may facilitate and IGF-BP-4 may inhibit the local actions of IGFs.
        </p>
        <p class="headingAnchor" id="H5525093">
         <span class="h2">
          TGF-beta
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transforming growth factor (TGF)-beta and the BMP family of proteins consist of at least 10 proteins that are produced by many different cells and that have multiple actions on growth and development [
         <a href="#rid159">
          159-161
         </a>
         ]. TGF-beta can inhibit bone resorption and stimulate bone formation. BMP-2 and other members of this family increase osteoblast differentiation and bone formation when injected subcutaneously or intramuscularly.
        </p>
        <p class="headingAnchor" id="H1206177">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhibition of bone formation is the major cause of glucocorticoid-induced osteoporosis and may be due to accelerated apoptosis of osteoblasts and osteocytes [
         <a href="#rid162">
          162
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">
          "Clinical features and evaluation of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1206184">
         <span class="h2">
          Thyroid hormones
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid hormones stimulate both bone resorption and formation. Thus, bone turnover is increased in hyperthyroidism, and bone loss can occur. (See
         <a class="medical medical_review" href="/z/d/html/7882.html" rel="external">
          "Bone disease with hyperthyroidism and thyroid hormone therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1206191">
         <span class="h2">
          Cytokines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytokines, produced by bone cells and adjacent hematopoietic and vascular cells, have multiple regulatory actions in the skeleton [
         <a href="#rid163">
          163-168
         </a>
         ]. Many of these factors have been implicated in the bone loss associated with ovariectomy in rodents. Regulation may occur as a result of both varying production of agonists and of changes in the receptors or binding proteins (receptor antagonists) for these factors.
        </p>
        <p class="headingAnchor" id="H1206198">
         <span class="h2">
          Fibroblast growth factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fibroblast growth factors (FGFs) are another family of proteins involved in skeletal development. Mutations in the receptors for these factors result in abnormal skeletal phenotypes, such as achondroplasia [
         <a href="#rid160">
          160
         </a>
         ]. Other growth factors such as vascular endothelial growth factor (VEGF) are produced in bone and may play a role in bone remodeling.
        </p>
        <p class="headingAnchor" id="H1206205">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other factors play an important role in bone metabolism [
         <a href="#rid159">
          159,161,169-172
         </a>
         ]. As examples, prostaglandins, leukotrienes, and nitric oxide may be critical in the rapid responses of bone cells to inflammation and mechanical forces. Prostaglandins have biphasic effects on bone resorption and formation, but the dominant effects in vivo are stimulatory [
         <a href="#rid170">
          170
         </a>
         ]. Prostaglandin production can be increased by impact loading and by inflammatory cytokines. Nitric oxide can inhibit osteoclast function [
         <a href="#rid173">
          173
         </a>
         ], while leukotrienes stimulate bone resorption [
         <a href="#rid174">
          174
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1207895">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skeletal structure and function
         </strong>
         – The skeleton is a highly dynamic organ that constantly undergoes changes and regeneration. It consists of specialized bone cells, mineralized and unmineralized connective tissue matrix, and spaces that include the bone marrow cavity, vascular canals, canaliculi, and lacunae containing osteocytes. The skeleton has both structural and metabolic functions. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skeletal development
         </strong>
         – Flat bones, including the vault of the skull, most of the upper facial skeleton, parts of the mandible, clavicle, and the pelvis, as well as the collar of long bones, arise from the direct conversion of undifferentiated mesenchymal cells into bone in a process called intramembranous bone formation. Axial and appendicular bone is formed from a cartilaginous template and is termed endochondral bone formation  (
         <a class="graphic graphic_figure graphicRef68827" href="/z/d/graphic/68827.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="local">
          'Skeletal development'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osteoblasts
         </strong>
         – The precursors of osteoblasts are multipotent mesenchymal stem cells  (
         <a class="graphic graphic_figure graphicRef79078" href="/z/d/graphic/79078.html" rel="external">
          figure 3
         </a>
         ). The process of differentiation of these progenitors to mature osteoblasts (ie, the cells capable of synthesizing the bone matrix) is accomplished by a sequential progression from the least differentiated and most proliferative cell to terminally differentiated cell that can no longer undergo mitosis. Runx2 and the Wnt signaling pathway are critical for the initiation of the osteoblast differentiation process and the commitment of multipotential precursors to osteoprogenitors. (See
         <a class="local">
          'Osteoblasts'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osteoclasts
         </strong>
         – Osteoclasts remove mineral and matrix to a limited depth on the trabecular surface or within cortical bone. They are formed by fusion of mononuclear precursors of the monocyte/macrophage lineage. The receptor activator of nuclear factor kappa B ligand (RANKL) and the macrophage colony-stimulating factor (M-CSF) are two cytokines that are essential for the development, function, and survival of osteoclasts. (See
         <a class="local">
          'Osteoclasts'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone modeling and remodeling
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Modeling
         </strong>
         – During development and growth, the skeleton is sculpted to achieve its shape and size by the removal of bone from one site and deposition at a different one; this process is called modeling. (See
         <a class="local">
          'Modeling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Remodeling
         </strong>
         – After the skeleton has reached maturity, regeneration continues in the form of a periodic replacement of old bone with new at the same location, a process called remodeling. (See
         <a class="local">
          'Remodeling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         All osteoclasts and osteoblasts belong to a unique temporary structure known as a bone multicellular unit (BMU)  (
         <a class="graphic graphic_picture graphicRef75617" href="/z/d/graphic/75617.html" rel="external">
          picture 1
         </a>
         ). Osteoclasts adhere to bone and subsequently remove it by acidification and proteolytic digestion. As the BMU advances, osteoclasts leave the resorption site and osteoblasts move in to cover the excavated area and begin the process of new bone formation by secreting osteoid, which is eventually mineralized into new bone. In normal adults, bone resorption and bone formation are tightly balanced so that the amount of bone formed in new BMUs equals the amount of bone resorbed. (See
         <a class="local">
          'Bone multicellular unit'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abnormal bone remodeling
         </strong>
         – An oversupply of osteoclasts relative to the need for remodeling or an undersupply of osteoblasts relative to the need for cavity repair are the seminal pathophysiological cellular changes in the most common bone diseases, including osteoporosis  (
         <a class="graphic graphic_diagnosticimage graphicRef72620" href="/z/d/graphic/72620.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef51633" href="/z/d/graphic/51633.html" rel="external">
          figure 7
         </a>
         ). (See
         <a class="local">
          'Abnormal bone remodeling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic and local regulators of bone cells
         </strong>
         – Several systemic hormones, cytokines, growth factors, and local signals influence the birth, death, and function of bone cells. The major systemic regulators are the calcium-regulating hormones, parathyroid hormone (PTH), calcitriol, growth hormone (GH)/insulin-like growth factor-1 (IGF-1), glucocorticoids, thyroid hormones, and sex hormones. Other factors, such as IGFs, have both systemic and local effects, and some have mainly or solely local effects, particularly prostaglandins, transforming growth factor (TGF)-beta, bone morphogenetic proteins (BMPs), and cytokines. (See
         <a class="local">
          'Systemic and local regulators of bone cells'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Zelzer E, McLean W, Ng YS, et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 2002; 129:1893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schipani E, Maes C, Carmeliet G, Semenza GL. Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J Bone Miner Res 2009; 24:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blin-Wakkach C, Lezot F, Ghoul-Mazgar S, et al. Endogenous Msx1 antisense transcript: in vivo and in vitro evidences, structure, and potential involvement in skeleton development in mammals. Proc Natl Acad Sci U S A 2001; 98:7336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wellik DM, Capecchi MR. Hox10 and Hox11 genes are required to globally pattern the mammalian skeleton. Science 2003; 301:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris SE, Guo D, Harris MA, et al. Transcriptional regulation of BMP-2 activated genes in osteoblasts using gene expression microarray analysis: role of Dlx2 and Dlx5 transcription factors. Front Biosci 2003; 8:s1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li H, Marijanovic I, Kronenberg MS, et al. Expression and function of Dlx genes in the osteoblast lineage. Dev Biol 2008; 316:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronenberg HM. Developmental regulation of the growth plate. Nature 2003; 423:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi T, Chung UI, Schipani E, et al. PTHrP and Indian hedgehog control differentiation of growth plate chondrocytes at multiple steps. Development 2002; 129:2977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mead TJ, Yutzey KE. Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development. Proc Natl Acad Sci U S A 2009; 106:14420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber JM, Calvi LM. Notch signaling and the bone marrow hematopoietic stem cell niche. Bone 2010; 46:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zalutskaya AA, Cox MK, Demay MB. Phosphate regulates embryonic endochondral bone development. J Cell Biochem 2009; 108:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berndt T, Kumar R. Novel mechanisms in the regulation of phosphorus homeostasis. Physiology (Bethesda) 2009; 24:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiela PR, Ghishan FK. Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest 2009; 89:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedenstein AJ, Chailakhyan RK, Latsinik NV, et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974; 17:331.
          </a>
         </li>
         <li class="breakAll">
          Owen M. Lineage of osteogenic cells and their relationship to the stromal system. In: Bone and Mineral Research, Peck WA (Ed), Elsevier, Amsterdam 1985. Vol 3, p.1.
         </li>
         <li class="breakAll">
          Triffitt JT. The stem cell of the osteoblast. In: Principles of Bone Biology, Bilezikian JP, Raisz LG, Rodan GA (Eds), Academic Press, San Diego 1996. p.39.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schor AM, Canfield AE, Sutton AB, et al. Pericyte differentiation. Clin Orthop Relat Res 1995; :81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizoguchi T, Ono N. The diverse origin of bone-forming osteoblasts. J Bone Miner Res 2021; 36:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pufe T, Scholz-Ahrens KE, Franke AT, et al. The role of vascular endothelial growth factor in glucocorticoid-induced bone loss: evaluation in a minipig model. Bone 2003; 33:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burkhardt R, Kettner G, Böhm W, et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone 1987; 8:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komori T. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res 2010; 339:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mundlos S, Otto F, Mundlos C, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997; 89:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee B, Thirunavukkarasu K, Zhou L, et al. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 1997; 16:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai M, Rosen CJ. PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 2010; 6:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malaval L, Modrowski D, Gupta AK, Aubin JE. Cellular expression of bone-related proteins during in vitro osteogenesis in rat bone marrow stromal cell cultures. J Cell Physiol 1994; 158:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu F, Malaval L, Aubin JE. The mature osteoblast phenotype is characterized by extensive plasticity. Exp Cell Res 1997; 232:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaur T, Lengner CJ, Hovhannisyan H, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 2005; 280:33132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamai K, Semenov M, Kato Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000; 407:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 2004; 131:1663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bienz M, Clevers H. Armadillo/beta-catenin signals in the nucleus--proof beyond a reasonable doubt? Nat Cell Biol 2003; 5:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu H, Hilton MJ, Tu X, et al. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005; 132:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005; 8:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill TP, Später D, Taketo MM, et al. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005; 8:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 2006; 133:3231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005; 280:21162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22:6267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19:1842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280:19883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellies DL, Viviano B, McCarthy J, et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 2006; 21:1738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007; 22:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodine PV, Seestaller-Wehr L, Kharode YP, et al. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol 2007; 210:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ott SM. Sclerostin and Wnt signaling--the pathway to bone strength. J Clin Endocrinol Metab 2005; 90:6741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laine CM, Joeng KS, Campeau PM, et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med 2013; 368:1809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002; 70:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002; 346:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mani A, Radhakrishnan J, Wang H, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007; 315:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 2005; 90:6392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoback D. Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab 2007; 92:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005; 37:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawakami K, Robling AG, Ai M, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem 2006; 281:23698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 2008; 3:e2942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005; 146:4577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 2007; 6:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrogini E, Almeida M, Martin-Millan M, et al. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab 2010; 11:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jilka RL, Almeida M, Ambrogini E, et al. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell 2010; 9:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almeida M, Han L, Martin-Millan M, et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007; 282:27285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickinson DA, Forman HJ. Glutathione in defense and signaling: lessons from a small thiol. Ann N Y Acad Sci 2002; 973:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almeida M, Han L, Martin-Millan M, et al. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 2007; 282:27298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almeida M, Ambrogini E, Han L, et al. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem 2009; 284:27438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manolagas SC, Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007; 21:2605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Vos KE, Coffer PJ. FOXO-binding partners: it takes two to tango. Oncogene 2008; 27:2289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoogeboom D, Burgering BM. Should I stay or should I go: beta-catenin decides under stress. Biochim Biophys Acta 2009; 1796:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeCarolis NA, Wharton KA Jr, Eisch AJ. Which way does the Wnt blow? Exploring the duality of canonical Wnt signaling on cellular aging. Bioessays 2008; 30:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia 2008; 51:1771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marotti G, Cane V, Palazzini S, et al. Structure-function relationships in the osteocyte. Ital J Min Electro Metab 1990; 4:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manolagas SC, Parfitt AM. What old means to bone. Trends Endocrinol Metab 2010; 21:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knothe Tate ML, Niederer P, Knothe U. In vivo tracer transport through the lacunocanalicular system of rat bone in an environment devoid of mechanical loading. Bone 1998; 22:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Wang Y, Han Y, et al. In situ measurement of solute transport in the bone lacunar-canalicular system. Proc Natl Acad Sci U S A 2005; 102:11911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev 1996; 17:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res 1997; 12:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishida N, Hayashi K, Hoshijima M, et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 2002; 277:41147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast formation. Nat Med 2011; 17:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emerton KB, Hu B, Woo AA, et al. Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone 2010; 46:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuller K, Wong B, Fox S, et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 2001; 358:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee NK, Choi YG, Baik JY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005; 106:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang S, Madyastha P, Bingel S, et al. A new superoxide-generating oxidase in murine osteoclasts. J Biol Chem 2001; 276:5452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim MS, Yang YM, Son A, et al. RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis. J Biol Chem 2010; 285:6913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levasseur R, Barrios R, Elefteriou F, et al. Reversible skeletal abnormalities in gamma-glutamyl transpeptidase-deficient mice. Endocrinology 2003; 144:2761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai XC, Lu D, Liu AL, et al. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J Biol Chem 2005; 280:17497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lean JM, Jagger CJ, Kirstein B, et al. Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 2005; 146:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrett IR, Boyce BF, Oreffo RO, et al. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990; 85:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ha H, Kwak HB, Lee SW, et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 2004; 301:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt NY, Kelley TW, Khramtsov VV, et al. Macrophage-colony-stimulating factor-induced activation of extracellular-regulated kinase involves phosphatidylinositol 3-kinase and reactive oxygen species in human monocytes. J Immunol 2002; 169:6427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lean JM, Davies JT, Fuller K, et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 2003; 112:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishii KA, Fumoto T, Iwai K, et al. Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 2009; 15:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Väänänen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000; 113 ( Pt 3):377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigoriadis AE, Wang ZQ, Cecchini MG, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodan SB, Rodan GA. Integrin function in osteoclasts. J Endocrinol 1997; 154 Suppl:S47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes DE, Dai A, Tiffee JC, et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996; 2:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007; 130:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin-Millan M, Almeida M, Ambrogini E, et al. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 2010; 24:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mentaverri R, Kamel S, Brazier M. Involvement of capacitive calcium entry and calcium store refilling in osteoclastic survival and bone resorption process. Cell Calcium 2003; 34:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen RH, Karsdal MA, Sørensen MG, et al. Dissolution of the inorganic phase of bone leading to release of calcium regulates osteoclast survival. Biochem Biophys Res Commun 2007; 360:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Key LL Jr, Rodriguiz RM, Willi SM, et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med 1995; 332:1594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robey PG. Vertebrate mineralized matrix proteins: structure and function. Connect Tissue Res 1996; 35:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moriishi T, Ozasa R, Ishimoto T, et al. Osteocalcin is necessary for the alignment of apatite crystallites, but not glucose metabolism, testosterone synthesis, or muscle mass. PLoS Genet 2020; 16:e1008586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manolagas SC. Osteocalcin promotes bone mineralization but is not a hormone. PLoS Genet 2020; 16:e1008714.
          </a>
         </li>
         <li class="breakAll">
          Frost HM. Bone remodeling and its relationship to metabolic bone diseases, Thomas, Springfield, Ill. 1973.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am 2003; 32:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994; 55:273.
          </a>
         </li>
         <li class="breakAll">
          Parfitt AM. Skeletal heterogeneity and the purposes of bone remodeling: implications for the understanding of osteoporosis. In: Osteoporosis, Marcus R, Feldman D, Kelsey J (Eds), Academic Press, San Diego 1996. p.315.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michael Parfitt A. Misconceptions V--Activation of osteoclasts is the first step in the bone remodeling cycle. Bone 2006; 39:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen TL, Sondergaard TE, Skorzynska KE, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 2009; 174:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Wan C, Deng L, et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 2007; 117:1616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wan C, Gilbert SR, Wang Y, et al. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A 2008; 105:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011; 17:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguirre JI, Plotkin LI, Stewart SA, et al. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 2006; 21:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herman BC, Cardoso L, Majeska RJ, et al. Activation of bone remodeling after fatigue: differential response to linear microcracks and diffuse damage. Bone 2010; 47:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manolagas SC. Perspective: Choreography from the tomb: an emerging role of dying osteocytes in the purposeful, and perhaps not so purposeful, targeting of bone remodeling. BoneKEy-Osteovision 2006; 3:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein RS, Wan C, Liu Q, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell 2010; 9:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci 2007; 1116:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKee MD, Nanci A. Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. Microsc Res Tech 1996; 33:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009; 15:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu X, Pang L, Lei W, et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 2010; 7:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qiu T, Wu X, Zhang F, et al. TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat Cell Biol 2010; 12:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 2011; 26:2317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002; 57:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paddock C, Youngs T, Eriksen E, Boyce R. Validation of wall thickness estimates obtained with polarized light microscopy using multiple fluorochrome labels: correlation with erosion depth estimates obtained by lamellar counting. Bone 1995; 16:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989; 4:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zelzer E, Olsen BR. The genetic basis for skeletal diseases. Nature 2003; 423:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vernejoul MC, Bénichou O. Human osteopetrosis and other sclerosing disorders: recent genetic developments. Calcif Tissue Int 2001; 69:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scimeca JC, Quincey D, Parrinello H, et al. Novel mutations in the TCIRG1 gene encoding the a3 subunit of the vacuolar proton pump in patients affected by infantile malignant osteopetrosis. Hum Mutat 2003; 21:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waguespack SG, Koller DL, White KE, et al. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 2003; 18:1513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med 2004; 351:2839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maranda B, Chabot G, Décarie JC, et al. Clinical and cellular manifestations of OSTM1-related infantile osteopetrosis. J Bone Miner Res 2008; 23:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feigin ME, Malbon CC. OSTM1 regulates beta-catenin/Lef1 interaction and is required for Wnt/beta-catenin signaling. Cell Signal 2008; 20:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007; 39:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henriksen K, Gram J, Høegh-Andersen P, et al. Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo. Am J Pathol 2005; 167:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001; 68:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005; 15:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007; 40:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dempster DW, Cosman F, Parisien M, et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997; 138:4607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishimori S, O'Meara MJ, Castro CD, et al. Salt-inducible kinases dictate parathyroid hormone 1 receptor action in bone development and remodeling. J Clin Invest 2019; 129:5187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon SH, Meyer MB, Arevalo C, et al. A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis. J Clin Invest 2023; 133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein RS, Underwood JL, Hutson MS, DeLuca HF. Bone histomorphometry in vitamin D-deficient rats infused with calcium and phosphorus. Am J Physiol 1984; 246:E499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taxel P, Kaneko H, Lee SK, et al. Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int 2008; 19:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997; 337:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002; 84-A:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen L, Li C, Qiao W, et al. A Ser(365)--&gt;Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum Mol Genet 2001; 10:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002; 23:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyaura C, Onoe Y, Inada M, et al. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc Natl Acad Sci U S A 1997; 94:9360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawaguchi H, Nemoto K, Raisz LG, et al. Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures. J Bone Miner Res 1996; 11:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz MC. Cytokines and estrogen in bone: anti-osteoporotic effects. Science 1993; 260:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onoe Y, Miyaura C, Kaminakayashiki T, et al. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 1996; 156:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin SC, Yamate T, Taguchi Y, et al. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest 1997; 100:1980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimble RB, Bain S, Pacifici R. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 1997; 12:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baek K, Bloomfield SA. Beta-adrenergic blockade and leptin replacement effectively mitigate disuse bone loss. J Bone Miner Res 2009; 24:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 1995; :36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mödder UI, Achenbach SJ, Amin S, et al. Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res 2010; 25:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bab I, Zimmer A, Melamed E. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann Med 2009; 41:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans DM, Ralston SH. Nitric oxide and bone. J Bone Miner Res 1996; 11:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia C, Boyce BF, Gilles J, et al. Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J Bone Miner Res 1996; 11:1619.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2053 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11934855" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19558314" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11390985" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Endogenous Msx1 antisense transcript: in vivo and in vitro evidences, structure, and potential involvement in skeleton development in mammals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12869760" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hox10 and Hox11 genes are required to globally pattern the mammalian skeleton.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12957859" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Transcriptional regulation of BMP-2 activated genes in osteoblasts using gene expression microarray analysis: role of Dlx2 and Dlx5 transcription factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18280462" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Expression and function of Dlx genes in the osteoblast lineage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12748651" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Developmental regulation of the growth plate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12050144" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : PTHrP and Indian hedgehog control differentiation of growth plate chondrocytes at multiple steps.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19590010" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19679213" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Notch signaling and the bone marrow hematopoietic stem cell niche.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19681042" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Phosphate regulates embryonic endochondral bone development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19196648" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Novel mechanisms in the regulation of phosphorus homeostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19029978" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4150881" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4150881" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4150881" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7543836" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pericyte differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34213032" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The diverse origin of bone-forming osteoblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14678846" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The role of vascular endothelial growth factor in glucocorticoid-induced bone loss: evaluation in a minipig model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3606907" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17956733" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9182763" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9182764" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19649655" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Regulation of bone development and extracellular matrix protein genes by RUNX2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9182765" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9207800" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11792318" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20820194" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : PPARγ: a circadian transcription factor in adipogenesis and osteogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8126078" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Cellular expression of bone-related proteins during in vitro osteogenesis in rat bone marrow stromal cell cultures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9141626" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The mature osteoblast phenotype is characterized by extensive plasticity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16043491" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11029007" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : LDL-receptor-related proteins in Wnt signal transduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15084453" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11955436" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12646868" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Armadillo/beta-catenin signals in the nucleus--proof beyond a reasonable doubt?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15576404" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Sequential roles of Hedgehog and Wnt signaling in osteoblast development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15866164" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15866163" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16854976" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15866165" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15802266" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Essential role of beta-catenin in postnatal bone acquisition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14633986" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16123173" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15778503" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17002572" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17032150" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17237793" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Dickkopf-1 is a master regulator of joint remodeling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17044082" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16330810" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Sclerostin and Wnt signaling--the pathway to bone strength.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23656646" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11719191" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11741193" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12015390" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : High bone density due to a mutation in LDL-receptor-related protein 5.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17332414" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : LRP6 mutation in a family with early coronary disease and metabolic risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16189254" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Bone mineral density in sclerosteosis; affected individuals and gene carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17341572" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Update in osteoporosis and metabolic bone disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15946907" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : SOST is a target gene for PTH in bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16790443" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18698360" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Control of bone mass and remodeling by PTH receptor signaling in osteocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16081646" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17971207" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20051526" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20142101" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20698835" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17623659" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12485918" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Glutathione in defense and signaling: lessons from a small thiol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17623658" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19657144" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17622581" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18391971" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : FOXO-binding partners: it takes two to tango.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19268509" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Should I stay or should I go: beta-catenin decides under stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18200563" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Which way does the Wnt blow? Exploring the duality of canonical Wnt signaling on cellular aging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18696049" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The WNT signalling pathway and diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Structure-function relationships in the osteocyte
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20223679" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : What old means to bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9477233" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : In vivo tracer transport through the lacunocanalicular system of rat bone in an environment devoid of mechanical loading.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16087872" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : In situ measurement of solute transport in the bone lacunar-canalicular system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8854048" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Advances in bone biology: the osteoclast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9169344" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Regulation of osteoclast function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12748652" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Osteoclast differentiation and activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12479813" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12171919" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21909103" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Matrix-embedded cells control osteoclast formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19925896" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Osteocyte apoptosis and control of bone resorption following ovariectomy in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9492069" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9730902" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9108485" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11498208" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Osteoprotegerin: a link between osteoporosis and arterial calcification?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18057140" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11204435" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The effect of a single dose of osteoprotegerin in postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15176987" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15817678" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11098048" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A new superoxide-generating oxidase in murine osteoclasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20048168" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12810527" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Reversible skeletal abnormalities in gamma-glutamyl transpeptidase-deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15731115" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15528306" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2312718" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15530848" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Reactive oxygen species mediate RANK signaling in osteoclasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12444151" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Macrophage-colony-stimulating factor-induced activation of extracellular-regulated kinase involves phosphatidylinositol 3-kinase and reactive oxygen species in human monocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12975476" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A crucial role for thiol antioxidants in estrogen-deficiency bone loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19252502" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10639325" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : The cell biology of osteoclast function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7939685" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9379137" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Integrin function in osteoclasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8837613" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17803905" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20053716" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12810059" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Involvement of capacitive calcium entry and calcium store refilling in osteoclastic survival and bone resorption process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17631274" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Dissolution of the inorganic phase of bone leading to release of calcium regulates osteoclast survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7753137" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Long-term treatment of osteopetrosis with recombinant human interferon gamma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11117749" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9084650" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Vertebrate mineralized matrix proteins: structure and function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32463816" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Osteocalcin is necessary for the alignment of apatite crystallites, but not glucose metabolism, testosterone synthesis, or muscle mass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32484816" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Osteocalcin promotes bone mineralization but is not a hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32484816" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Osteocalcin promotes bone mineralization but is not a hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12699291" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : The structural and biomechanical basis of the gain and loss of bone strength in women and men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7962158" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7962158" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16963327" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Misconceptions V--Activation of osteoclasts is the first step in the bone remodeling cycle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19095960" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : A physical mechanism for coupling bone resorption and formation in adult human bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17549257" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18184809" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21909105" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Evidence for osteocyte regulation of bone homeostasis through RANKL expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16598381" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20633708" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Activation of bone remodeling after fatigue: differential response to linear microcracks and diffuse damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Perspective: Choreography from the tomb: an emerging role of dying osteocytes in the purposeful, and perhaps not so purposeful, targeting of bone remodeling
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20047574" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17646259" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Osteocytes as dynamic multifunctional cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8845514" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19584867" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21040899" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20139972" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21812031" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10782361" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12017554" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Sex steroids and bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7786642" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Validation of wall thickness estimates obtained with polarized light microscopy using multiple fluorochrome labels: correlation with erosion depth estimates obtained by lamellar counting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2658477" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Bone histomorphometry in glucocorticoid-induced osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2188141" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12748653" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : The genetic basis for skeletal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11685426" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Human osteopetrosis and other sclerosing disorders: recent genetic developments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12552563" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Novel mutations in the TCIRG1 gene encoding the a3 subunit of the vacuolar proton pump in patients affected by infantile malignant osteopetrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12929941" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15625335" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Osteopetrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17922613" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Clinical and cellular manifestations of OSTM1-related infantile osteopetrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18296023" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : OSTM1 regulates beta-catenin/Lef1 interaction and is required for Wnt/beta-catenin signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17632511" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16251418" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11179006" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15965026" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17517365" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8119233" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Anabolic actions of parathyroid hormone on bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9348185" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31430259" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Salt-inducible kinases dictate parathyroid hormone 1 receptor action in bone development and remodeling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36862513" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6377910" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Bone histomorphometry in vitamin D-deficient rats infused with calcium and phosphorus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17768586" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9211678" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Effect of testosterone and estradiol in a man with aromatase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12063342" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : The role of growth factors in the repair of bone. Biology and clinical applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11181569" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : A Ser(365)--&gt;Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12466190" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Genetic analysis of the mammalian transforming growth factor-beta superfamily.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9664068" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9256487" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8852946" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Interleukin-4 inhibits prostaglandin G/H synthase-2 and cytosolic phospholipase A2 induction in neonatal mouse parietal bone cultures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8480174" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Cytokines and estrogen in bone: anti-osteoporotic effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8543830" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329961" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9169353" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19113907" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Beta-adrenergic blockade and leptin replacement effectively mitigate disuse bone loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7641496" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : The role of prostaglandins in the regulation of bone metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19594297" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Relation of serum serotonin levels to bone density and structural parameters in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19634029" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Cannabinoids and the skeleton: from marijuana to reversal of bone loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8852940" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Nitric oxide and bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8915769" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
